Gene therapy’s next act: new vectors, big funding, and a race to the brain
The gist
Gene therapy for the brain is entering a new era with next-gen vectors, major funding, and a race to deliver breakthrough treatments for neurological diseases.
What to know
- Apertura and Broad Institute’s TfR1 CapX™ capsid enables scalable IV delivery to the brain and spinal cord—now freely available to academics via the Open Aperture program.
- JCR’s JUST-AAV platform and Encoded’s NociPro element are raising the bar for safety and precision, targeting hard-to-reach cell types while slashing off-target effects.
- Latus Bio just banked $97M to push novel AAV therapies for Huntington’s and CLN2 into human trials by late 2026, promising lower doses and broader access.
TfR1 CapX™ Breaks Barriers
Apertura and Broad Institute’s TfR1 CapX™ not only enables IV gene delivery to the brain but is now freely available to academics, igniting a new era of open, collaborative CNS research.
By early 2026, Apertura Gene Therapy, in collaboration with scientists from the Broad Institute, unveiled TfR1 CapX™, a groundbreaking AAV capsid engineered to surmount the formidable barriers of CNS targeting via intravenous delivery. Demonstrating scalable clinical manufacturing alongside effective transduction of both brain and spinal cord tissues, TfR1 CapX™ represents a significant leap forward in gene therapy vectors designed for neurological diseases. This innovation was spotlighted at the 2026 ASGCT Annual Meeting, where presentations also highlighted complementary advances in capsid engineering and gene-editing strategies leveraging TfR1 CapX™ to tackle complex neurological disorders.
In a strategic move to accelerate CNS gene therapy research, Apertura launched the Open Aperture program, granting free academic access to TfR1 CapX™. This initiative fosters broad collaboration across the scientific community, enabling researchers to explore and expand upon this novel capsid’s potential without traditional access barriers. By democratizing access to TfR1 CapX™, Apertura aims to catalyze innovation and expedite the development of targeted treatments for neurological diseases.
Vector Engineering Gets Precise
JCR’s mini-antibody AAVs and Encoded’s cell-type targeting elements are redefining safety and pinpointing delivery, setting new standards for gene therapy precision and tolerability.
By early 2026, JCR Pharmaceuticals' JUST-AAV platform marked a significant advance in vector engineering by incorporating miniaturized antibodies to enhance tissue specificity and mitigate liver toxicity in AAV-based gene therapies. This innovative approach refines targeted delivery, addressing a critical safety concern that has long challenged gene therapy vectors, thereby improving therapeutic precision without compromising patient safety.
Encoded Therapeutics further pushed the boundaries of precision vector platforms with their development of cell-type selective regulatory elements, exemplified by the NociPro element that selectively targets nociceptive neurons to knock down Na V 1.7. This specificity not only enhances tolerability but also supports the clinical promise of ETX301 for post-amputation neuroma pain, illustrating how finely tuned regulatory control can translate into improved therapeutic outcomes.
Expanding on their precision engineering capabilities, Encoded Therapeutics demonstrated the versatility and safety of their intravenous AAV-miRNA therapy for Angelman syndrome, achieving a substantial 57% increase in UBE3A protein expression across key brain regions in non-human primates. This achievement underscores the platform's potential to deliver durable, one-time treatments with broad neurological reach while maintaining a favorable safety profile, signaling a transformative step for gene therapies targeting complex brain disorders.
Latus Bio’s $97M Bet on CNS
Armed with major funding, Latus Bio is racing to human trials with scalable, low-dose gene therapies for Huntington’s and CLN2, aiming to reshape access and efficacy for hard-to-treat diseases.
By mid-2026, Latus Bio has emerged as a frontrunner in translating targeted gene therapies for neurological diseases, having secured a substantial $97 million Series A round to propel its lead candidates—LTS-201 for Huntington’s disease and LTS-101 for CLN2—toward IND submissions and first-in-human trials slated for Q3 2026. This financial backing underpins their strategy to overcome traditional gene therapy hurdles by leveraging proprietary engineered AAV capsids and optimized delivery routes, enabling scalable, low-dose treatments that promise enhanced safety, efficacy, and cost-effectiveness across a spectrum of disorders including CNS, kidney, and muscle diseases.
Encoded Therapeutics complements this clinical momentum with precision vector engineering showcased at ASGCT 2026, where their NociPro regulatory element demonstrated selective targeting and potent knockdown of Na V 1.7 in nociceptive neurons, advancing ETX301 for post-amputation neuroma pain with improved specificity and tolerability. Moreover, their preclinical intravenous AAV-miRNA therapy for Angelman syndrome achieved a remarkable 57% increase in UBE3A protein expression across key brain regions in non-human primates, highlighting the potential for durable, one-time gene therapies that could redefine treatment paradigms for CNS disorders.
